ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone Measurement While Treating Prostate Cancer: Which Test and When?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 158320" data-attributes="member: 3"><p>The Canadian consensus statement recommends achieving a serum testosterone level of less than 0.7nmol/l as there appears to be an associated clinical benefit9. Additional recommendations include regular monitoring of testosterone and PSA levels throughout the first year of ADT treatment, using validated LC-MS/MS methods for testosterone assays at low testosterone levels (<0.7 nmol/l) (0r 20 ng/dL)</p><p></p><p>In conclusion, lower testosterone levels correlate with better freedom from CRPC. Breakthrough testosterone levels above 1.7 nmol/l have higher rates of failure. Testosterone levels should be assessed periodically to ensure castrate levels (every 3- months), with confirmation of lab assays at low testosterone levels. Lastly, the role of testosterone and other serum androgens as prognostic and predictive biomarkers in mCRPC requires more study.</p><p><a href="https://www.urotoday.com/conference-highlights/apccc-2019/114636-apccc-2019-testosterone-measurement-which-test-and-when.html" target="_blank">APCCC 2019: Testosterone Measurement - Which Test and When?</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 158320, member: 3"] The Canadian consensus statement recommends achieving a serum testosterone level of less than 0.7nmol/l as there appears to be an associated clinical benefit9. Additional recommendations include regular monitoring of testosterone and PSA levels throughout the first year of ADT treatment, using validated LC-MS/MS methods for testosterone assays at low testosterone levels (<0.7 nmol/l) (0r 20 ng/dL) In conclusion, lower testosterone levels correlate with better freedom from CRPC. Breakthrough testosterone levels above 1.7 nmol/l have higher rates of failure. Testosterone levels should be assessed periodically to ensure castrate levels (every 3- months), with confirmation of lab assays at low testosterone levels. Lastly, the role of testosterone and other serum androgens as prognostic and predictive biomarkers in mCRPC requires more study. [URL="https://www.urotoday.com/conference-highlights/apccc-2019/114636-apccc-2019-testosterone-measurement-which-test-and-when.html"]APCCC 2019: Testosterone Measurement - Which Test and When?[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone Measurement While Treating Prostate Cancer: Which Test and When?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top